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Type 2 diabetes mellitus (T2D) is emerging as a worldwide public health problem, and is mainly associated with an
increased incidence of obesity. Bariatric surgery is currently considered the most effective treatment for severely
obese patients. After bariatric surgery, T2D patients have shown a significant improvement in glycemic control,
even before substantial weight loss and often discontinuation of medication for diabetes control. A central role for
enteroendocrine cells from the epithelium of the gastrointestinal tract has been speculated in this postoperative
phenomenon. These cells produce and secrete polypeptides - gut hormones - that are associated with regulating
energy intake and glucose homeostasis through modulation of peripheral target organs, including the endocrine
pancreas. This article reviews and discusses the biological actions of the gut hormones ghrelin, cholecystokinin,
incretins, enteroglucagon, and Peptide YY, all of which were recently identified as potential candidates for
mediators of glycemic control after bariatric surgery. In conclusion, current data reinforce the hypothesis that T2D
reversion after bariatric surgery may be related to glycemic homeostasis developed by the intestine.
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Type 2 diabetes mellitus (T2D) and obesity are major and
increasingly common global health problems [1-4] that are
often associated with each other. This relationship involves
two main defects: insulin resistance (i.e., decreased
capacity of insulin to stimulate glucose uptake in insulin-
dependent tissues and to suppress endogenous glucose
release, mainly from the liver) and β cell dysfunction
resulting in decreased insulin secretion [5]. The systemic
insulin resistance in obesity can be initiated largely in adi-
pose tissue. Macrophage-mediated tissue inflammation is a
core mechanism of dysfunction in adipose tissue. Adipose
tissue can communicate with the liver and other organs,
such as, muscle and pancreas, and release proinflammatory
cytokines leading to reduction of insulin sensitivity [6].
Intervention programs to promote a healthy lifestyle,
such as nutritional therapy, physical exercises, and pharma-
cotherapy, are extensively used in several combinations to
fight obesity. Unfortunately, with very rare exceptions, the
weight loss is usually quite modest, especially in severely* Correspondence: sala.priscila@gmail.com
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unless otherwise stated.obese persons [5,7,8]. Bariatric surgery is increasingly
being acknowledged as an efficient method of treating
severely obese patients (Body Mass Index [BMI] ≥40 kg/m2)
and/or patients with a grade II obesity (BMI ≥35) to achieve
the remission of obesity-associated comorbidities, including
T2D [9-11].
There are many different surgical procedures aiming
body weight loss in severely obese patients, and they can
be classified as techniques restrictives (e.g., reduction of
gastric volume, such as AGB and SG), malabsorptives
(e.g., intestinal bypass, such as DJB), or mixed (combi-
nation of restrictive and malabsorptive techniques, such
as BPD, BPD-DS and RYGB), as follows in Table 1.
Notably, glycemic homeostasis after bariatric surgery
depends on the kind of surgical technique applied. After
restrictive procedures, glycemic homeostasis takes lon-
ger to establish and is largely related to weight loss [15],
while full T2D remission is observed within days or a
few weeks [10,22,23] after malabsorptive or mixed surgi-
cal procedures [24], even before significant weight loss
takes place. Currently, Roux-en-Y gastric bypass (RYGB)
is considered the gold standard technique among the
bariatric surgery procedures [11,20,21].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Bariatric surgeries: mainly types and descriptions
Principle Type Description
Restrictive
Adjustable gastric band (AGB) Involves an inflatable band that is placed around the upper portion of the stomach, creating a
small stomach pouch above the band, and the rest of the stomach below the band. The size of
the stomach opening can be adjusted by filling the inflatable band with sterile saline, which is
injected through a port placed under the skin [12].
Sleeve gastrectomy (SG) Also known as vertical gastrectomy. The procedure removes the gastric fundus and body,
leaving a gastric tube along the lesser curve [13].
Malabsorptive
Duodenojejunal bypass (DJB) The pylorus is preserved and the length of the biliopancreatic limb is 70 cm from the ligament
of Treitz. The Roux limb is 100 cm long. The duodenum and jejunum are bypassed for the
nutrient flow. This technique is presently an experimental procedure [9,14,15].
Mixed
Biliopancreatic diversion (BPD) This technique consist in a reduction of gastric pouch (70±10 mL), an alimentary limb
composed of 400 cm, a common limb of 100 cm, and a biliopancreatic limb, the remainder of
the small intestine [16].
Biliopancreatic diversion with
duodenal switch (BPD-DS)
Adaptation from the biliopancreatic diversion. is a procedure with two components. First, a
smaller, tubular stomach pouch is created by removing 70% of portion of the stomach, very
similar to the sleeve gastrectomy. Next, a large portion of the small intestine is bypassed
[12,17-19].
Roux-en-Y gastric bypass (RYGB) Consists in the reduction of the gastric food reservoir (to a capacity of 30 to 50 mL) and
excludes the passage of nutrients through the remaining stomach, duodenum, and proximal
jejunum, with an isolated Y-shaped jejunal loop being anastomosed to the small stomach
pouch [20,21].
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surgical technique, such as, AGB is 48%, compared to
84% after RYGB. The hypoglycemic effects of malab-
sorptive or mixed surgical procedures appear not to
depend only on body weight loss [25-28].
The gastrointestinal tract is quite important for the con-
trol of energetic homeostasis. Enteroendocrine cells from
the coating epithelium of the gastrointestinal tract pro-
duce and secrete polypeptides that can activate neural
circuits that, in turn, communicate to peripheral organs,
including the liver, muscular tissue, adipose tissue, and
islets of Langerhans in the pancreas. Through such pro-
perties, these hormones may play important roles in food
control and in glycemic homeostasis [6,14,29-32].
To explain the early remission of T2D after bariatric sur-
gery, we recently reviewed hypotheses proposing that ana-
tomical changes arise from malabsorptive procedures with
metabolic modifications of the small intestine [29]. Here,
we discuss evidence linking these metabolic modifications
to the biological actions of gut hormones, such as ghrelin,
cholecystokinin, incretins, enteroglucagon, and Peptide
YY, all of which were recently identified as potential candi-
dates for inducing glycemic control after bariatric surgery,
reinforcing the concept of “metabolic surgery” [30].
There are two mainly hypotheses about the mecha-
nisms of T2D remission after bariatric surgery. Both of
them involve change in gut hormones: Hindgut hypo-
thesis and foregut hypothesis [29].
The hindgut hypothesis proposed by Cummings et al.
[31] suggested that the production of the insulinotropic
gut hormones, such as GLP-1 and PYY, are stimulated
when nutrients arrive directly to the distal intestine,contributing to the reversion of hyperglycemia, even in
the absence of any gastric restriction.
On the other hand, in foregut hypotheses proposed by
Rubino, et al. [33], suggested that in susceptible indivi-
duals, the surgical deviation of the proximal intestine in-
hibits the release of diabetogenic signals, such as GIP,
which release can be induced by the presence of food in
the duodenum. When food stops flowing through the
duodenum and the proximal jejunum after RYGB, this/
these factor (s), called “anti-incretin,” is/are inhibited.
Therefore, the glycemic control contributes to T2D remis-
son. GIP appears to have a dual function concerning gly-
cemic control; it is able to reduce glycemia (insulinotropic
effect), but is also able to increase glycemia (glucagonotro-
pic effect). In T2D patients, GIP has less insulinotropic
power, behaving mainly as a glucagonotropic hormone in
these patients [34,35]. Therefore, this hypothesis has been
considered of major scientific importance, but its validity
still needs to be confirmed. See in Table 2 some mainly
studies that correlate changes in intestinal hormones after
different surgical techniques.
Ghrelin
Ghrelin is currently the only known intestinal hormone
with orexigenic functions [41]. This 28-amino acid protein
is derived from pre-proghrelin. Ghrelin is synthesized
mainly by the gastric X/A cells and the small intestine—to
a lesser extent—based on increased distance from the
pylorus. Ghrelin experiences unique post-translational
acylation in which serine residue 3 is covalently connected
to octanoic acid to form acyl-ghrelin. This acylation is
necessary for ghrelin to connect to the growth hormone

























AGB ↔ ↑ ↔ Ø Ø ↔ ↔ ↔ ↔ Ø Ø ↔ ↔
SG ↓ ↓ ↔ ↑ ↔ ↑ Ø Ø Ø Ø ↔ ↑ ↓ ↑
BPD ↔ ↑ ↔ Ø Ø ↔ ↑ ↑ ↓ ↓ Ø Ø ↑ ↑ Ø
BPD-
DS
↓ Ø Ø Ø Ø Ø Ø Ø Ø Ø ↑ ↑
RYGB ↔ ↑ ↓ ↔↓ ↔ ↑ ↔ ↑ ↔ ↔ ↔ ↑ ↔ ↑
Legend - *Evidence was obtained from both human and animal published studies. No studies were found about gut hormones and DJB. Abbreviations - AGB
Adjustable Gastric Band, VBG Vertical Banded Gastroplasty, SG Sleeve Gastrectomy, JB Jejunoileal Bypass, DJB Duodenojejunal Bypass, BPD Biliopancreatic
Diversion, BPD-DS Biliopancreatic Diversion with Duodenal Switch, RYGB Roux-en-Y Gastric Bypass. ↔: No significant change in the majority of studies;
↑: Significant increased in the majority of studies; ↓: Significant decreased in the majority of the studies; Ø: No studies for this parameter; PP: postprandial; CCK:
Cholecystokinin; GLP-1: Glucagon Like Peptide-1; GIP: Glucose-dependent insulinotropic polypeptide; OXM: Oxyntomodulin; PYY: Peptide YY.
Adapted from: [36].
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brain barrier [42]. In the hypothalamus, ghrelin concentra-
tions rise during fasting and before meals to stimulate
appetite and digestive secretions [9,41,43,44]. Experimen-
tally, the chronic administration of ghrelin causes hyper-
phagia and increases adiposity [9].
Glucose homeostasis is also influenced by ghrelin.
Ghrelin likely increases plasma glucose through the stimu-
lation of the insulin counter-regulatory hormone glucagon,
to suppress the insulin-sensitizing hormone adiponectin,
which blocks the hepatic signal for insulin at the level of
phosphoinositide 3-kinase and inhibits insulin secretion [9].
Ghrelin increases the secretion of glucagon in the endo-
crine pancreas in vitro, but whether this occurs in vivo is
still unknown [45].
Studies have shown that inactivation of the pre-
proghrelin gene in lean rats reduces the level of fasting
glycemia and endogenous glucose production, and in-
creases the level of glucose-stimulated insulin compared
to wild-type rats. These data indicate that ghrelin limits
gluconeogenesis and the synthesis of glycogen mediated
by insulin [45]. In addition, the suppression of ghrelin in
ob/ob rat models of diabetes reduces glycemia and fast-
ing insulin and improves glucose tolerance [43,45,46].
In humans, the plasma concentration of ghrelin is in-
versely correlated with the degree of adiposity and changes
in BMI and body weight. Obese individuals have a lower
circulating level of ghrelin, though this level is increased if
these individuals undergo diet-induced weight loss [9,46].
The effect of bariatric surgery on the plasma concentra-
tion of ghrelin is controversial. An increase in ghrelin is
expected with weight loss, but this increase does not al-
ways occur, and reduction in plasma ghrelin levels is also
observed [17,45]. These apparently paradoxical findings
may be explained by the application of different surgical
techniques.
The highest ghrelin concentration occurs in the gastric
fundus. Its production decreases when this area is dis-
connected, as may occur after bariatric surgery involvingproximal gastric resection. Plasma ghrelin is also signifi-
cantly reduced after RYGB, although it increases in
obese individuals who experience similar levels of diet-
induced weight loss. Permanent absence of food in the
stomach and duodenum in the context of gastric bypass
may result in a continuous stimulatory signal to inhibit
ghrelin, favoring weight loss after surgery [47]. On the
other hand, the plasma concentration of ghrelin is high
after procedures that leave the gastric fundus and the
vagal nerve intact, such as after adjustable gastric band
implantation. However, if a small amount of ghrelin-
producing tissue remains after surgery, postoperative
plasma concentration of ghrelin may not change [17,48].
Considering the physiological properties of ghrelin, a
decrease in plasma levels after surgery likely plays an
important role in the mediation of weight loss and the
beneficial metabolic effects of bariatric surgery [9].
The recent Swiss multicenter randomized study [49]
compared, in 217 obese patients, two surgical techniques:
RYGB (n:110), a mixed technique, and laparoscopic sleeve
gastrectomy ((LSG) n:107) a restrictive technique. There
were no differences in body mass index (BMI), age, co-
morbidities and feeding behavior between the groups. The
mean operative time was shorter for LSG than for RYGB.
Complications (<30 days) had a tendency to occur more
often in RYGB than LSG (p=0.067). However, the differ-
ence of serious complications was not statistically signifi-
cant (p=0.21). Body weight loss was similar in both groups
after one year of surgery (p=0.2). The authors concluded
that LSG could be performed in shorter time than RYGB
and have a trend toward fewer complications than RYGB.
Both techniques showed similar efficiency in body weight
loss and improvement in associated comorbidities, with
the exception for gastroesophageal reflux, better resolved
after RYGB. It calls attention that T2D was efficiently
treated by both surgeries techniques without differences
among them [49].
SG improves glucose metabolism as effectively as
RYGB. The underlying mechanism is still not clear but,
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could be involved in this mechanism. Inactive ghrelin (des
acyl ghrelin) is activated to acyl ghrelin in the stomach
through the action of the ghrelin O-acyltransferase enzyme
(GOAT) - the active form of ghrelin. The inhibition of
GOAT activity may be consequence of SG technique.
Moreover, ghrelin may exerts its orexigenic action through
specific modulation of Sirtuin1 (SIRT1)/p53 and AMP-
actived protein kinase (AMPK) pathways, which increase
the agouti-related protein (AgRP) and neuropeptide Y
(NPY) expression in the hypothalamic arcuate nucleus
(ARC). Ghrelin triggers a sharp rise at the hypothalamic
regulation of mammalian target of rapamycin signaling
pathway (mTOR) [51]. There is reciprocal interaction
between mTOR pathways and ghrelin/GOAT axis. After
SG, the reduced food intake is signaled as peripheral nega-
tive energy balance, with the consequent mTOR activity
inhibition. This would have stimulated the gastric ghrelin
production and secretion and food intake signaling in the
hypothalamus. However, the stomach cannot handle this
situation, as the ghrelin-producing X/A cell volume is
significantly reduced in SG.
Martins L, et al, [51] demonstrated that the central in-
hibition of mTOR signaling with rapamycin decreased the
orexigenic action of ghrelin and normalized mRNA
expression of NPY and AgRP as well as its major down-
stream transcription factors, ie, the protein cAMP
response-element binding protein (pCREB) and forkhead
box O1 (FoxO1 total and phosphorylated). In summary,
mTOR activation is a hypothalamic, mainly ARC-located,
mechanism mediating ghrelin’s action on feeding through
increased AgRP and NPY gene expression. The activation
of hypothalamic mTOR signaling seems to be a mediator
of food intake, of potential importance for the understan-
ding and treatment of obesity. Therefore, the GOAT
activity down regulation induces activation of mTOR.
Secretion of insulin induced by glucose can be enhanced
and resolution of T2D achieved [50,51].
Cholecystokinin
Cholecystokinin (CCK) acts in satiety control, vesicular
contraction, pancreatic and gastric acid secretion, and
glucose homeostasis. The CCK peptide is produced by
the I cells present mainly in the duodenum and jejunum
and is secreted in response to nutrients in the intestinal
lumen, particularly lipids and proteins [43,52]. CCK
levels increase rapidly and peak 15 min after meals [53].
CCK has two main receptors, CCK1R and CCK2R.
CCK1R appears to be responsible for reduction of food
intake [42], while CCK2R mediates the control of
glucose homeostasis by the pancreas. In vitro, CCK sti-
mulates glucagon release by human pancreatic islets and
increases pancreatic β cell proliferation [43]. However,
experimentally, CCK also stimulates insulin secretion ina glucose-dependent manner. In addition, the infusion of
a form of CCK with eight amino acids (CKK-8) in T2D
subjects increases the plasma concentration of insulin
and reduces postprandial glucose after meals [43]. Few
studies in humans have linked CCK with bariatric surgery.
A pioneering study that evaluated patients receiving RYGB
failed to detect changes in the plasma concentration of
CCK 10 months after the surgery [53].
Few studies were conducted to evaluate CCK. How-
ever, Mumphrey et al, [37] in an experimental study
assessed the long term effect of RYGB in enteroendo-
crine cells. Numbers of CCK cells were significantly in-
creased in the Roux and common limbs, but not the
biliopancreatic limb in RYGB rats. The findings suggest
that the number of enteroendocrine cells increases pas-
sively as the gut adapts, and that the increased total
number of I cells is likely to contribute to the higher cir-
culating levels of CCK, potentially leading to suppression
of food intake and stimulation of insulin secretion [37].
Until recently, CCK has not received much attention,
probably because no changes in the postprandial CCK-
response to a mixed protein-fat meal were reported 6
months after RYGB in an early study [38]. However, re-
cently it was reported that postprandial CCK response
was significantly increased 2 weeks after RYGB [39]. Dif-
ference in the postprandial CCK response was also found
between patients with RYGB or SG. RYGB had a signifi-
cant duodenal exclusion effect on CCK [54]. One year
postoperatively, CCK concentrations after test meals in-
creased less in the RYGB group than SG group, with the
latter show significantly higher maximal CCK concentra-
tions [40]. More consistent findings were reported in pa-
tients after jejuno-ileal bypass surgery, with postprandial
CCK levels significantly increased 3 months [55] and even
20 years after surgery [56]. The proximal jejunum was
anastomosed to the terminal ileum. This technique has
been confirmed as effective for weight loss, though serious
complications led to abandoning it in the 1970s [57].Incretins
Incretins are enteric hormones considered to be insulino-
tropic due to their capacity to stimulate postprandial
insulin secretion. The incretin concept is based on the
observation of a greater insulin response to oral glucose
compared to intravenous glucose. Substances derived from
the intestine and released as a consequence of oral nutri-
ent intake (incretins) were considered potential secre-
tagogues of insulin [58]. These findings support the
hypothesis that the gluco-regulatory process results from
the interaction of pancreatic hormones (insulin and gluca-
gon) and intestinal hormones; in addition, these findings
reinforce the concept that T2D may arise from different
hormone systems [59].
Figure 1 Post-translational processing of proglucagon in
different tissues. Legend: Abbreviations - GRPP: glicentin-related
pancreatic peptide; GLP-1: glucagon-like peptide 1; GLP-2:
glucagon-like peptide 2. Adapted from [63].
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tide (GIP) and glucagon-like peptide-1 (GLP-1) [58,60].
These proteins act directly on pancreatic β cells, which ex-
press G protein-coupled receptors (GPCRs) for both GLP-
1 and GIP. Stimulation of these receptors increases cyclic
adenosine monophosphate (cAMP) concentrations, which,
in turn, increases insulin secretion under permissible con-
ditions, such as the presence of high plasma glycemia [61].
GIP is a 42-amino acid peptide cleaved from its precursor
peptide, proGIP. Its nomenclature arose from its ability to
inhibit gastric acid secretion. Both active [GIP (1–42)] and
inactive [GIP (3–42)] forms of GIP are produced by K cells
in the duodenum and jejunum under the presence of glu-
cose and fat in the duodenum. GIP also stimulates insulin
secretion and is currently being called glucose-dependent
insulinotropic polypeptide [58,60]. No effects on glucagon
secretion have been experimentally reported during
episodes of hyperglycemia, suggesting that GIP-mediated
glucagon secretion depends on hypoglycemia [62].
GLP-1 and GLP-2 are cleaved from the precursor pro-
glucagon by intestinal endocrine L cells, which are located
mainly in the distal ileum and colon [60]. Proglucagon is
mainly expressed in the L cells of the intestine and α cells
of the endocrine pancreas. The primary transcripts and
translation products of the proglucagon gene are identical
in the two types of cells, but post-translational processing
of proglucagon differs in a tissue-specific manner, resul-
ting mainly in a bioactive glucagon peptide in the pancreas
and GLPs in the intestine (Figure 1) [60,63].
In the enteroendocrine L cells, GLP-1 and GLP-2 are
produced by prohormone convertase 1/3 (PC 1/3) action.
Post-translational processing leads to multiple circulating
forms of GLP-1: the inactive forms GLP-1 (1–37) and
GLP-1 (1–36) and the biologically active forms, including
the N-terminal peptides GLP-1 (7–37) and GLP-1 (7–36)
amide. Both active peptides are powerful insulinotropics.
On the other hand, GLP-2 has powerful intestinotropic
properties on the proliferation and apoptosis of the intes-
tinal mucosa, but does not stimulate insulin secretion
[44,60,62,64,65].
GLP-1 (7–37) largely stimulates pancreatic β cells to se-
crete insulin after postprandial glycemic increases [42,44].
GLP-1 (7–36) is the most frequent active form of GLP-1
in the circulation and reduces serum levels of glucose by
stimulating insulin secretion [66]. GLP-1 preserved and
even increased β cell mass in cultures of isolated human
pancreatic islets, while the destruction of GLP-1 receptors
increased β cell apoptosis [46,62]. The fasting levels of
GLP-1 are low, but increase after the ingestion of mixed
meals or meals rich in fat and carbohydrates. In addition
to stimulating insulin secretion, GLP-1 suppresses the
release of glucagon, decelerates gastric emptying, im-
proves insulin sensitivity, and reduces food consump-
tion [58,60].In humans, GIP and GLP-1 concentrations in the
circulation increase within 15 min after a meal and reach
a peak (~200 to 50 pmol/L, respectively) between 30 to
45 min after a meal, returning to baseline concentrations
after 2–3 hours. The interaction between the incretins
GLP-1 and GIP is responsible for approximately 50% of
postprandial insulin increase. Both incretins have a half-
life of 3 to 5 min due to the enzymatic actions of dipep-
tidyl peptidase IV (DPP-IV), which quickly converts the
active forms of GLP-1 and GIP into their inactive me-
tabolites [64,65].
DPP-IV, also known as CD26, is a ubiquitous enzyme
widely expressed in several tissues and cell types, includ-
ing the kidneys, lungs, adrenal gland, liver, intestines,
testes, pancreas, central nervous system, and on the sur-
face of lymphocytes and macrophages. In addition to the
form linked on the surface of cells, a soluble protein
form of this enzyme is found in the circulation [60,67].
Because of the wide distribution of DPP-IV, GLP-1
undergoes rapid degradation. Approximately 25% of the
secreted hormone reaches the venous circulation in an
intact form, 40% to 50% is cleaved in the liver, and only
10% to 15% reaches the peripheral circulation as intact
GLP-1 [62].
Patients with T2D are incretin-deficient. This deficit
appears to occur due to the reduced secretion of GLP-1
and to the impaired insulinotropic effect of GIP. In these
patients, the plasma concentrations of GLP-1 are dimi-
nished, but the biological effect of GLP-1 in stimulating
insulin secretion is preserved. Explanations for these ob-
servations include defective expression and downregula-
tion of GIP receptors in pancreatic β cells, while the
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not yet known [48]. There is a lack of substantial studies
evaluating the effect of bariatric surgery on GLP-1 levels,
but available results suggest that postprandial GLP-1
consistently increases soon after malabsorptive bariatric
surgery, while purely restrictive procedures do not change
postprandial GLP-1 levels [46].
In opposition to GLP-1, the plasma concentrations of
GIP are normal in T2D patients, but the effect of GIP on
insulin secretion is affected [58,68]. Some studies report
the effect of bariatric surgery on GIP plasma levels. Under
fasting conditions, this hormone has been found to be ei-
ther reduced or unchanged after surgical interventions
that lead to the malabsorption of food. Postprandial levels
of GIP are reduced in obese patients 2 weeks after jejuno-
ileal bypass [69] or RYGB. Postprandial levels of GIP are
also reduced in obese patients with T2D after bilio-
pancreatic derivation [70,71], but increased 1 month after
gastric bypass [72,73]. Studies evaluating the effect of
restrictive surgical procedures on plasma levels of GIP
reported no changes at least 23 months after implantation
of an adjustable gastric band [74,75]. Recently it has been
speculated that GIP stimulates pancreatic glucagon secre-
tion and stimulates pancreatic β cell growth, leading a
glucagonotropic effect in T2D patients [34,35].
Enteroglucagon
The enteroglucagon peptide, also coded by the progluca-
gon gene, is expressed primarily in the L cells of the
distal intestine. The term enteroglucagon refers to the
intestinal GLPs—mainly glicentin and oxyntomodulin
(OXM) [76].
Glicentin is a 69-amino acid peptide with no clearly de-
fined biological activity. This hormone may stimulate the
secretion of insulin and inhibit glucagon, but glicentin also
appears to inhibit the secretion of gastric acid and to regu-
late intestinal motility [76,77]. However, with the discovery
of the structure of proglucagon, some researchers consider
glicentin only a discarded metabolite of proglucagon after
the cleavage of GLP-1 and GLP-2 [76,78].
OXM is a 37-amino acid peptide that mainly reduces
gastric acid secretion, but it also acts directly in the hypo-
thalamic centers to reduce appetite and caloric ingestion.
OXM increases insulin secretion and prevents pancreatic
β cell apoptosis. Similar to GLP-1, OXM is inactivated
rapidly by DPP-IV [53]. OXM can decrease serum con-
centrations of ghrelin by approximately 15% to 20% in ro-
dents and by 44% in humans [21]. The specific OXM
receptor has not yet been identified, although it acts as a
double agonist for the GLP-1 receptor with a very low af-
finity (50 times weaker than that of GLP-1) [52,76,79,80].
A randomized study evaluated OXM levels in 20 obese
women with T2D 1 month after RYGB (n = 10) and diet-
induced equivalent weight loss (n = 10). The oral glucosetolerance test (OGTT) was accompanied by an increase of
OXM only after bariatric surgery. The increase of OXM
was significantly correlated with an increase in hormones
GLP-1 and PYY (3–36). This result is not surprising, as
long as OXM is secreted along with these hormones by
the intestinal L cells. The authors concluded that changes
in plasma concentrations of OXM occurred mainly in re-
sponse to the surgical intervention and not as a conse-
quence of weight loss, which may partly explain the
success of the surgery in regards to T2D resolution [79].
Further studies about the effect of different bariatric
surgery techniques on enteroglucagon expression in the
small intestine are necessary.
Peptide YY
Peptide tyrosine tyrosine (PYY) is composed of 36 amino
acids, with tyrosine (Y) as the first and last in the se-
quence [21]. This hormone belongs to the pancreatic
polypeptide (PP) family and is released by the intestinal
L cells, mainly in the ileum, colon, and rectum [44,81].
The action of PYY is to inhibit gastrointestinal motility
and exocrine pancreas and gastric secretions [81]. The
circulating concentration of PYY is low during fasting,
increases rapidly after a meal, with a peak after 1 to
2 hours, and remains high for several postprandial hours
[59]. PYY secretion is proportional to the caloric density
of the food eaten, and higher levels are observed after
consuming lipids and carbohydrates [17].
After the secretion of PYY, DPP-IV cleaves the N-
terminal of its orexigenic form (1–36), producing its anor-
ectic form (3–36) [78]. The activity of DPP-IV is increased
in obese individuals. High plasma concentrations of this
enzyme, with resulting increases in PYY (3–36) [82], are
observed after bariatric surgery. In fact, a postprandial re-
sponse of increased PYY is evident in the earliest post-
surgical period, specifically after malabsorptive bariatric
surgery, even before weight loss occurs. Le Roux et al. [83]
and Morínigo et al. [84] observed increased postprandial
levels of PYY and GLP-1 at 2 days and within 6 months
after RYGB, respectively.
The truncate form PYY (3–36), which is released after a
meal, induces satiety via the Y2 receptor expressed in the
hypothalamus [45]. The main peripheral action of PYY is
to reduce lipolysis, but PYY also increases insulin sensiti-
vity by decreasing the concentration of circulating fatty
acids. Studies in rats have shown that PYY (3–36) re-
inforces the action of insulin in improving glycemic
control, regardless of eating habits and weight loss [85,86].
Regarding the mechanisms of gastrointestinal hormo-
nal action in the hypothalamic signaling, the beginning
of the food intake process results in the release of
anorexigenic hormones, such as: GLP-1, PYY, CCK and
GIP. This result in the activation of neuropeptides, such
as neurons Proopiomelanocortin (POMC) and cocaine
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curs in the postprandial state, decreasing the appetite.
On the other hand, the release of the orexigenic hor-
mone ghrelin and the activation of the neuropeptides
NPY and AgRP occurs in the fasting state, increasing the
appetite. The gastrointestinal peptides can activate vagal
afferent neurons or can act directly on the hypothalamus
[42,87] (Figure 2).
Bariatric surgery: remission of T2D and its recurrence
According to Clinical Practice Guidelines for the Peri-
operative Nutritional, Metabolic, and Nonsurgical Support
of the Bariatric Surgery Patient—2013 [88], significant body
weight regain or failure to lose body weight should prompt
evaluation or (a) decreased patient adherence with lifestyle
modification, (b) evaluation of medications associated with
body weight gain or impairment of body weight loss, (c)
development of maladaptive eating behaviors, (d) psycho-
logical complications, and (e) radiographic or endoscopic
assessment to assess pouch enlargement, anastomotic dila-
tion, formation of a gastric fistula among patients who
underwent a RYGB, or inadequate band restriction among
patients who underwent AGB. In patients with or with-
out complete resolution of T2D, continued management
should be performed. Routine metabolic and nutritional
monitoring is recommended after all bariatric surgical
procedures [88].
A meta-analyse has found the resolution of T2D in
approximately 80% of obese diabetic patients who have
had RYGB and BPD–DS surgeries. Conversely, the reso-
lution rates are slightly lower with restrictive-only proce-
dures but are still greater than any available diabeticFigure 2 Gastrointestinal hormones and hypothalamic signaling. Lege
POMC: Proopiomelanocortin; CART: cocaine and amphetamine-regulated tr
Cholecystokinin; OXM: Oxyntomodulin; GIP: Glucose-depedent insulinotropmedical therapy [89]. A recent randomized study com-
pared, for T2D 150 patients, the effect of only intensive
medical therapy versus intensive medical therapy plus
RYGB or SG surgery. The authors assessed outcome after
3 years post randomization. The primary end point was a
glycated hemoglobin level of 6.0% or less, which was met
by 5% of the patients in the medical-therapy group, as
compared with 38% of those in the RYGB (p<0.001) and
24% of those in the SG group (p=0.01). The use of medica-
tions for glycemic control, was lower in the surgical
groups than in the medical-therapy group [90].
The beneficial effects on glucose homeostasis after
bariatric surgery are likely due, in large part, to the effect
of body weight loss on insulin sensitivity and possibly
additional beneficial effects on β cell function and the
metabolic response to feeding. Furthermore, it has been
observed that those obese patients with shorter duration
of T2D (less than 5 years), mild forms of T2D (no insu-
lin requirements) and having the greatest body weight
loss are more likely to have a remission of T2D when
compared with those with longer duration of the disease
or chronic T2D (more than 10 years), and are on insulin
therapy [91]. The remission rate in patients with T2D
for ≤5 years was 95% compared to 75% in patients who
had diabetes for 6 to 10 years and 54% in those who had
diabetes for more than 10 years (p<0.001) [92,93]. It is
accepted that the duration and severity of T2D is in-
versely correlated to the likelihood to its remission after
surgery, may be due, in part, by chronic and acquired β
cell dysfunction [91].
Hall et al. [28] showed that patients with HbA1c >10%
had a 50% rate of remission compared to 77.3% with annd: Abbreviations – NPY: Neuropeptide Y; AgRP: agouti-related protein;
anscript; GLP-1: Glucagon Like Peptide-1; PYY: Peptide YY; CCK:
ic polypeptide.
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operatively was 5.5±7 years. A preoperative duration of
T2D >10 years was shown to significantly reduce the
chances of remission of T2D. A short period of time
with diabetes and good glycemic control before surgery
may result in a better remission rate for diabetes, sug-
gesting that bariatric surgery should be performed earlier
in T2D patients than it is done nowadays. In addition,
not all bariatric procedures have the same effect on body
weight and glycemic homeostasis for T2D control [28].
Chikunguwo et al. [92] in a retrospective long-term
study analyzed 177 T2D patients who had undergone
RYGB. Early remission of T2D occurred in 89% of patients
after RYGB and T2D recurrence happened in 43.1%. Dur-
able (>5-year) resolution of T2D was greatest in the pa-
tients who originally had either controlled their T2D with
diet (76%) or oral hypoglycemic agents (66%). The rate of
T2D remission was more likely to be durable in men
(p=.00381). Body weight regain was statistically significant,
but a weak predictor, of T2D recurrence [92].
DiGiorgi studying 42 RYGB patients with T2D and > 3
years of follow-up has shown that T2D had either resolved
or improved in all patients (64% and 36%, respectively);
but in 24% recurred or worsened. The patients with re-
currence or worsening had had a lower preoperative
BMI than those without recurrence or worsening (p=.05),
regained a greater percentage of their body lost weight
(p =.002), had a greater body weight loss failure rateFigure 3 General schematic representation of the mechanisms after R
diabetes control. Legend: RYGB can control food intake through gastroint
emptying. In the liver, there is insulin sensitivity improvement, with decrea
decrease of inflammation and production oh proinflammatory cytokines, im
increase and all these change leads to T2D remission. Abbreviations: GLP-1(p=.03), and had greater postoperative glucose levels
(p=.0002). Patients who required insulin or oral medica-
tion before RYGB were more likely to experience improve-
ment rather than resolution [93].
A retrospective study comparing the long-term effects
of SG, RYGB and AGB on T2D, was performed with 60
morbidly obese T2D patients. The mean follow-up period
was 36 months. The T2D resolution rate was 60.8% for
the AGB technique, 81.2% for RYGB and 80.9% for the SG
technique. The resolution rate remained constant at 36-
month follow-up evaluation in both the RYGB and SG
group, but not at AGB group. The authors have concluded
that, for 3-year follow-up, all three bariatric procedures
are effective in treating diabetes, but the AGB procedure
was the least effective. The antidiabetic effect was similarly
earlier after RYGB and SG compared with AGB. This
difference may indicate that a hormonal mechanism may
be involved, independent of body weight loss [94].
Considered the gold standard, RYGB is the most com-
monly used bariatric surgery technique worldwide
(Figure 3).
Critical points of RYGB
A recent systematic review and meta-analysis for bariatric
surgery confirmed the substantial positives effects in obes-
ity and metabolic conditions, however, calls attention for
the risks of complication, reoperation, and death. A total
of 164 studies were included (37 randomized clinical trialsYGB that contribute for glycemic homeostasis and type 2
estinal hormones action. The reduced gastric pouch favors gastric
se of insulin resistance and glucose output. In adipose tissue occurs
proving insulin sensitivity. In the pancreas the release of insulin
: Glucagon Like Peptide-1; PYY: Peptide YY; OXM: Oxyntomodulin.
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patients. The mortality rate within 30 days was 0.08%, and
after 30 days was 0.31%. The complication rate was 17%.
The reoperation rate was 7%. RYGB was more effective in
body weight loss however was associated with more com-
plications. AGB had lower mortality and complication
rates; yet, the reoperation rate was higher than RYGB. SG
appeared to be more effective in weight loss than AGB
and comparable with RYGB. In general, surgical complica-
tions included all adverse events associated with bariatric
surgery, such as bleeding, stomal stenosis, leak, vomiting,
reflux, gastrointestinal symptoms, and nutritional and
electrolyte abnormalities [95].
Final considerations
There are several hypotheses regarding metabolic changes
induced by bariatric surgery, which may be associated with
T2D remission. All of the hypotheses involve or can be as-
sociated with the metabolic properties of the intestine.
Two hypotheses consistently suggest that the pathophysi-
ology of T2D involves an imbalance in incretins and the
release of other insulinotropic hormones (considered anti-
diabetogenic signals; hindgut hypothesis), as well as the re-
lease of still-undetermined anti-incretin factors (considered
diabetogenic signals; foregut intestine hypothesis) [34].
Glucagon is considered a strong candidate for a diabeto-
genic signal because T2D is associated with little secretion
of insulin and excessive release of glucagon [78]. Glucagon
is originated by the cleavage of proglucagon expressed by
both α pancreatic cells and L intestinal cells. Therefore,
glucagon can be produced by the intestine, mainly by the
distal portion of the small intestine. As illustrated in
Figure 1, the transcription and translation of the progluca-
gon gene vary in the pancreas and intestine. In the pan-
creas, these processes result in the production of the
hormones glucagon, glicentin-related pancreatic peptide
(GRPP), and major proglucagon fragment (MPGF). In the
intestine, this process results in the production of the
hormones GLP-1, GLP-2, glicentin, and OXM [33,34,36].
The GIP hormone is one important factor that may
contribute to the increase of glucagon in T2D patients.
In these patients, GIP has less insulinotropic and more
glucagonotropic actions and was found to be decreased
after malabsorptive bariatric surgery. The reduced gluca-
gonotropic signaling of GIP could contribute to the res-
toration of normal glucose tolerance observed after this
kind of procedure. Thus, GIP has been considered as a
diabetogenic signal produced by the duodenum that is
excluded after surgery [29,33-36].
Data of recurrence of T2D after RYGB and others tech-
niques are still limited. However the weight is observed in
approximately 50% of the patients (46% within 24 months
and 63.6% within 48 months) [96]. Chikunguwo SM et al,
showed that weigh regain occurred between 18 and 24montgs after surgert in 30% of patients [92]. Some factors
can influence in weigh regain after surgery, such as, type
of surgery performed, in which we realized in clinical
practice that the more malabsorptive technique, lower the
regained weight; presence of eating disorders; patient ad-
herence to the support groups and pre surgical BMI [96].
Although many studies discuss only remission rates of
T2D after bariatric surgery, dates about durability of this
remission are limited. Some studies show that the durabi-
lity of T2D remission is correlated with sustained weigh
loss. This remission of T2D is more durable in patients
with less severe diabetes in preoperative period, using ei-
ther diet or oral hypoglycemic agents to glycemic control.
Patients with use of insulin have more chance of T2D re-
currence after bariatric surgery. Durable remission corre-
lated most closely with an early disease stage of T2D [92].
Conclusion
Obesity is associated with an increased risk of developing
insulin resistance and T2D. The systemic insulin resist-
ance in obesity can be initiated largely in adipose tissue,
and macrophage-mediated tissue inflammation is a core
mechanism of dysfunction in adipose tissue. Adipose tis-
sue can communicate with the liver and other organs,
such as, muscle and pancreas, and release proinflamma-
tory cytokines leading to insulin sensitivity. When insulin
resistance is accompanied by dysfunction of pancreatic
islet β-cells, failure to control blood glucose levels results.
Abnormalities in β-cell function are therefore critical in
defining the risk and development of T2D.
Bariatric surgery involves changes in gastrointestinal
anatomy and has been shown to be effective in the treat-
ment of obesity and obesity-associated comorbidities.
The early remission of T2D after RYGB appears to be a
direct consequence of gastrointestinal anatomy rebuild-
ing and not exclusively a result of decreased food intake
and/or weight loss. Until now, is not clear which hypo-
thesis is more accept and consistent for improvement in
glycemic control after surgery. However, the hindgut hy-
pothesis has been suggested as a potent mechanism to
TDM remission, because the plasma levels of hormones
GLP-1 and PYY are increased in obese patients with
T2DM after surgeries with a malabsorptive component,
such as RYGB surgeries, as discussed previously by our
group in a recent review. We believe that in addition to
PYY and GLP-1 are strong candidates for this hypothesis,
another unknown factors release by lower intestine, can
be involved in glycemic normalization following RYGB.
Current evidence, although restricted to a small num-
ber of studies, consistently supports a potential role for
some intestinal hormones in improving diabetes after
RYGB, highlighting the importance of understanding the
intestine as a metabolically active organ that may be
managed in the future to improve health.
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